AbbVie Inc. (ABBV)
| Market Cap | 192.87B |
| Revenue (ttm) | 53.73B |
| Net Income (ttm) | 6.66B |
| Shares Out | 1.77B |
| EPS (ttm) | 3.71 |
| PE Ratio | 29.43 |
| Forward PE | 7.89 |
| Dividend | $5.08 (4.65%) |
| Ex-Dividend Date | Oct 14, 2021 |
| Volume | 4,614,352 |
| Open | 108.67 |
| Previous Close | 108.76 |
| Day's Range | 108.31 - 109.21 |
| 52-Week Range | 75.49 - 120.07 |
| Beta | 0.83 |
| Analysts | Buy |
| Price Target | 127.01 (+16.4%) |
| Est. Earnings Date | Oct 29, 2021 |
About ABBV
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, mar...
Financial Performance
In 2020, AbbVie's revenue was $45.80 billion, an increase of 37.69% compared to the previous year's $33.27 billion. Earnings were $4.62 billion, a decrease of -41.44%.
Financial StatementsAnalyst Forecast
According to 22 analysts, the average rating for AbbVie stock is "Buy." The 12-month stock price forecast is 127.01, which is an increase of 16.37% from the latest price.
News
AbbVie (ABBV) Earnings Expected to Grow: Should You Buy?
AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Could This Beaten-Down Biotech Stock Be the Next Buyout Target?
This gene-therapy specialist may need some help turning things around.
3 Biopharma Stocks To Watch Following Johnson & Johnson's Earnings Beat
Johnson & Johnson (NYSE:JNJ) shares are higher Tuesday following the release of its third-quarter results. J&J A Bellwether For The Sector: Given the timing of J&J's earnings release and its portfolio b...
3 Leading Healthcare Stocks to Buy in 2021 and Beyond
Three healthcare stocks that have momentum on their side and are good buys right now.
AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know
AbbVie (ABBV) closed the most recent trading day at $107.43, moving -1.74% from the previous trading session.
7 Blue Chips to Shield Your Portfolio From Market Downturn
Blue-chip stocks that have growing cash flow, good value, and have strong growth are suitable investments as the market downturn worsens. The post 7 Blue Chips to Shield Your Portfolio From Market Downt...
3 High-Yield Dividend Stocks I'm Not Selling Anytime Soon
I'm not yielding with these great dividend stocks.
3 Best Dividend Stocks for Retirement
These companies have positioned themselves to provide a generous and rising income stream.
2 Buffett Stocks to Buy and Hold Forever
The Oracle of Omaha is largely a set-and-forget kind of investor and you should be, too.
AbbVie Receives CHMP Positive Opinion for Risankizumab (SKYRIZI®) for the Treatment of Adults with Active Psoriatic A...
NORTH CHICAGO, Ill., Oct. 15, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended the approva...
Want More Monthly Income? Invest in These 3 Stocks
They all pay more than double what you'll get with the average stock in the S&P 500.
AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know
In the latest trading session, AbbVie (ABBV) closed at $110.34, marking a -0.76% move from the previous day.
This is Why AbbVie (ABBV) is a Great Dividend Stock
Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes?
Allergan Aesthetics Launches Series of Initiatives to Support Breast Cancer Awareness
IRVINE, Calif., Oct. 11, 2021 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company (NYSE: ABBV), is continuing its commitment to breast health, awareness, restoration, and research in support of breas...
AbbVie Touts Additional Rinvoq Data In Inflammatory Spinal Arthritis
AbbVie Inc (NYSE: ABBV) has churned out new data for Rinvoq in the hope that adding more evidence will back the JAK inhibitor's megablockbuster potential. Related: AbbVie Submits Upadacitinib Applicat...
Why AbbVie Stock Sank in September
A regulatory setback weighed on the drugmaker's shares last month.
AbbVie's Upadacitinib (RINVOQ®) Met Primary and Most Ranked Secondary Endpoints in Phase 3 Study for Non-Radiographic...
NORTH CHICAGO, Ill., Oct. 7, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive top-line results from Study 2 of the Phase 3 SELECT-AXIS 2 clinical trial in adults with active non-radiogr...
AbbVie's RINVOQ® (upadacitinib) Met Primary and All Ranked Secondary Endpoints in Phase 3 Study in Ankylosing Spondyl...
NORTH CHICAGO, Ill., Oct. 7, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive top-line results from the first of two studies of the Phase 3 SELECT-AXIS 2 clinical trial evaluating the e...
AbbVie to Host Third-Quarter 2021 Earnings Conference Call
NORTH CHICAGO, Ill., Oct. 5, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its third-quarter 2021 financial results on Friday, October 29, 2021, before the market opens.
AbbVie (ABBV) Stock Moves -0.33%: What You Should Know
AbbVie (ABBV) closed the most recent trading day at $108.73, moving -0.33% from the previous trading session.
AbbVie to Showcase New Data at the United European Gastroenterology (UEG) Week Virtual 2021
NORTH CHICAGO, Ill., Oct. 2, 2021 /PRNewswire/ -- AbbVie today announced new data on the investigational use of risankizumab (SKYRIZI®) in Crohn's disease, upadacitinib (RINVOQ®) in ulcerative colitis a...
Here's What Warren Buffett Looks For With Healthcare Stocks
There's a reason why there are so few of them in his portfolio.